Format

Send to

Choose Destination
Cytokine Growth Factor Rev. 2014 Aug;25(4):415-21. doi: 10.1016/j.cytogfr.2014.07.017. Epub 2014 Aug 1.

IL-12-and IL-23 in health and disease.

Author information

1
Institute of Experimental Immunology, University of Zürich, Zürich, Switzerland. Electronic address: andrewlewis.croxford@uzh.ch.
2
Institute of Experimental Immunology, University of Zürich, Zürich, Switzerland.

Abstract

Interleukin (IL)-12 and IL-23 play important roles in the development of experimental autoimmune disease models and numerous afflictions affecting humans. Preclinical data over the last 20 years combined with successful clinical trials has identified a clear relationship between IL-12, IL-23 and the generation of pathogenic T helper cells capable of orchestrating tissue inflammation. Observations made in the clinic have shown that IL-12p40, a common subunit shared by IL-12 and IL-23, is critical to pathologies associated with psoriasis, inflammatory bowel disease (IBD) and tumor growth. These advancements have set in motion the development of a number of potential therapeutics aimed at manipulating IL-12/23 signaling pathways in both mice and humans. This review will discuss a brief history of the understanding and expansion of the IL-12 cytokine family, some difficulties associated with preclinical data interpretation and finally the medicinal interventions that have been developed to combat IL-12/23-driven autoimmune disorders.

KEYWORDS:

Autoimmunity; Cytokines; IL-12 family; Inflammation; Treatment

PMID:
25130295
DOI:
10.1016/j.cytogfr.2014.07.017
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center